Passage BIO, Inc. (PASG) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Passage BIO is a clinical-stage genetic medicines company focused on neurodegenerative diseases. Its lead product candidate, PBFT02, is a gene replacement therapy for frontotemporal dementia (FTD) caused by progranulin deficiency (FTD-GRN). The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(7,749) | $(19,340) | $(32,539) | $(52,042) |
| Net Loss Per Share (Basic/Diluted) | $(2.44) | $(6.15) | $(10.26) | $(17.04) |
| Cash and Cash Equivalents (End of Period) | $52,773 (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(691,774) (as of Sept 30, 2025) | |||
| Operating Cash Flow (9M) | $(25,030) | $(39,512) |
Material Changes vs. Prior Period
- Expense Reduction: Net loss decreased significantly in Q3 2025 compared to Q3 2024, driven by a 50% reduction in Research and Development (R&D) expenses and a 40% reduction in General and Administrative (G&A) expenses. This follows a January 2025 workforce reduction of approximately 55% and the cessation of lab operations in Hopewell, New Jersey.
- Impairment Charges: The company recorded no impairment of long-lived assets in Q3 2025, compared to $4.8 million in Q3 2024. For the nine months ended September 30, 2025, impairment charges were $2.6 million, primarily related to the sale of laboratory equipment.
- Liquidity Position: Cash and cash equivalents increased to $52.8 million from $37.6 million at year-end 2024. This increase was driven by the maturity of marketable securities ($39.0 million) and a net cash increase from investing activities, offset by operating cash outflows.
- Reverse Stock Split: A 1-for-20 reverse stock split was effected on July 14, 2025, to regain compliance with Nasdaq listing requirements. All share and per-share data have been retroactively adjusted.
Guidance, Outlook, and Risks
- Cash Runway: Management expects existing cash and cash equivalents to fund operating expenses and capital expenditure requirements into the first quarter of 2027.
- Clinical Progress: The company is advancing the upliFT-D Phase 1/2 trial for PBFT02. As of November 2025, dosing for Cohorts 1 and 2 is complete. The company plans to report updated interim safety and biomarker data from Dose 2 in the first half of 2026 and seek regulatory feedback on registrational trial design in the first half of 2026.
- Outlicense Transaction: The company has outlicensed three pediatric programs (GM1, Krabbe, MLD) to Gemma Biotherapeutics. While $13.8 million in payments has been received, revenue recognition is deferred until performance obligations are met or collectibility is assured.
- Risks: Key risks include the need for substantial additional capital to achieve profitability, the uncertainty of clinical trial outcomes for PBFT02, reliance on third-party manufacturers (Catalent) and collaborators (Gemma), and potential regulatory delays. The company has no products approved for commercial sale.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $52.8 million cash balance against the projected runway into Q1 2027, considering potential delays in clinical milestones.
- Revenue Recognition: Monitor the status of the $13.8 million in non-refundable payments from Gemma to determine when, if ever, these will be recognized as revenue under ASC 606.
- Clinical Safety Data: Review upcoming interim data (H1 2026) regarding the serious adverse events (SAEs) observed in the upliFT-D trial, specifically venous sinus thrombosis and pulmonary embolism, and the efficacy of the new prophylactic anticoagulation protocol.
- Manufacturing Capacity: Assess the impact of the Catalent acquisition by Novo Holdings A/S on the company's ability to secure clinical and future commercial supply.
- Stock Liquidity: Evaluate the impact of the 1-for-20 reverse stock split on trading volume and market maker support.